Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by David T. Rubin and Russell D. Cohen.

 
Connection Strength
 
 
 
8.931
 
  1. Cohen RD, Feuerstein JD, Rubin DT. Reply. Gastroenterology. 2021 06; 160(7):2627.
    View in: PubMed
    Score: 0.900
  2. Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020 Jul; 159(1):350-357.
    View in: PubMed
    Score: 0.850
  3. Cohen RD, Lewis JR, Turner H, Harrell LE, Hanauer SB, Rubin DT. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.455
  4. Cohen NA, Choi D, Choden T, Cleveland NK, Cohen RD, Rubin DT. Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data from a Large Tertiary Center. Clin Gastroenterol Hepatol. 2022 Apr 02.
    View in: PubMed
    Score: 0.244
  5. Akiyama S, Ollech JE, Traboulsi C, Rai V, Glick LR, Yi Y, Runde J, Olivas AD, Weber CR, Cohen RD, Olortegui KBS, Hurst RD, Umanskiy K, Shogan BD, Rubin MA, Dalal SR, Sakuraba A, Pekow J, Chang EB, Hart J, Hyman NH, Rubin DT. Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis. Dig Dis Sci. 2022 Aug; 67(8):4020-4031.
    View in: PubMed
    Score: 0.243
  6. Runde J, Erondu A, Akiyama S, Traboulsi C, Rai V, Glick LR, Yi Y, Ollech JE, Cohen RD, Skowron KB, Hurst RD, Umanskiy K, Shogan BD, Hyman NH, Rubin MA, Dalal SR, Sakuraba A, Pekow J, Chang EB, Rubin DT. Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch-Anal Anastomosis in Pediatric Ulcerative Colitis. Inflamm Bowel Dis. 2022 Jan 18.
    View in: PubMed
    Score: 0.240
  7. Akiyama S, Ollech JE, Rai V, Glick LR, Yi Y, Traboulsi C, Runde J, Cohen RD, Skowron KB, Hurst RD, Umanskiy K, Shogan BD, Hyman NH, Rubin MA, Dalal SR, Sakuraba A, Pekow J, Chang EB, Rubin DT. Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes. Clin Gastroenterol Hepatol. 2022 02; 20(2):293-302.e9.
    View in: PubMed
    Score: 0.225
  8. Ollech JE, Dwadasi S, Rai V, Peleg N, Normatov I, Israel A, Sossenheimer PH, Christensen B, Pekow J, Dalal SR, Sakuraba A, Cohen RD, Rubin DT. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020 03; 51(6):637-643.
    View in: PubMed
    Score: 0.208
  9. Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis. 2019 Sep 19; 13(9):1105-1110.
    View in: PubMed
    Score: 0.204
  10. Glick LR, Sossenheimer PH, Ollech JE, Cohen RD, Hyman NH, Hurst RD, Rubin DT. Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. J Crohns Colitis. 2019 Sep 19; 13(9):1158-1162.
    View in: PubMed
    Score: 0.204
  11. Buisson A, Mak WY, Andersen MJ, Lei D, Kahn SA, Pekow J, Cohen RD, Zmeter N, Pereira B, Rubin DT. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug 14; 13(8):1012-1024.
    View in: PubMed
    Score: 0.203
  12. Israel A, Christensen B, El Jurdi K, Rai V, Ollech JE, Cohen RD, Sakuraba A, Dalal SR, Rubin DT. Follow-Up of Patients With Ulcerative Colitis and Histological Normalization. Clin Gastroenterol Hepatol. 2020 04; 18(4):987-988.e1.
    View in: PubMed
    Score: 0.201
  13. Sossenheimer PH, Glick LR, Dachman AH, Skowron KB, Rubin MA, Umanskiy K, Smith R, Cannon LM, Hurst RD, Cohen RD, Hyman NH, Rubin DT. Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. Dis Colon Rectum. 2019 04; 62(4):463-469.
    View in: PubMed
    Score: 0.198
  14. Weisshof R, Aharoni Golan M, Sossenheimer PH, El Jurdi K, Ollech JE, Pekow J, Cohen RD, Sakuraba A, Dalal S, Rubin DT. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
    View in: PubMed
    Score: 0.196
  15. Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT. Correction to: Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 10; 63(10):2815.
    View in: PubMed
    Score: 0.191
  16. Yarur AJ, Gondal B, Hirsch A, Christensen B, Cohen RD, Rubin DT. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
    View in: PubMed
    Score: 0.188
  17. Krugliak Cleveland N, Ollech JE, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Hurst R, Rubin DT. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206.
    View in: PubMed
    Score: 0.186
  18. Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
    View in: PubMed
    Score: 0.184
  19. Mak WY, Buisson A, Andersen MJ, Lei D, Pekow J, Cohen RD, Kahn SA, Pereira B, Rubin DT. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018 May; 63(5):1294-1301.
    View in: PubMed
    Score: 0.183
  20. Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
    View in: PubMed
    Score: 0.183
  21. Krugliak Cleveland N, Huo D, Sadiq F, Sofia MA, Marks J, Cohen RD, Hanauer SB, Turner J, Hart J, Rubin DT. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
    View in: PubMed
    Score: 0.182
  22. Gyawali B, Parsad S, Feinberg BA, Nabhan C. Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance. JCO Precis Oncol. 2017 Nov; 1:1-5.
    View in: PubMed
    Score: 0.179
  23. Gyawali B, Parsad S, Feinberg BA, Nabhan C. Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance. JCO Precis Oncol. 2017 Nov; 1:1-5.
    View in: PubMed
    Score: 0.179
  24. Gyawali B, Parsad S, Feinberg BA, Nabhan C. Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance. JCO Precis Oncol. 2017 Nov; 1:1-5.
    View in: PubMed
    Score: 0.179
  25. Gyawali B, Parsad S, Feinberg BA, Nabhan C. Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance. JCO Precis Oncol. 2017 Nov; 1:1-5.
    View in: PubMed
    Score: 0.179
  26. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791.
    View in: PubMed
    Score: 0.175
  27. Saad AM, Czul F, Sakuraba A, Rubin DT, Cohen RD. Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis. 2016 May; 22(5):1027-31.
    View in: PubMed
    Score: 0.162
  28. Krugliak Cleveland N, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Rubin DT. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
    View in: PubMed
    Score: 0.160
  29. Stein AC, Rubin DT, Hanauer SB, Cohen RD. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
    View in: PubMed
    Score: 0.145
  30. Sakuraba A, Annunziata ML, Cohen RD, Hanauer SB, Rubin DT. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
    View in: PubMed
    Score: 0.136
  31. Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J, Turner JR. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4.
    View in: PubMed
    Score: 0.133
  32. Sakuraba A, Keyashian K, Correia C, Melek J, Cohen RD, Hanauer SB, Rubin DT. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
    View in: PubMed
    Score: 0.130
  33. Leung Y, Kaplan GG, Rioux KP, Hubbard J, Kamhawi S, Stasiak L, Cohen RD, Devlin SM, Panaccione R, Hanauer SB, Rubin DT. Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32.
    View in: PubMed
    Score: 0.121
  34. Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007 Jun; 65(7):998-1004.
    View in: PubMed
    Score: 0.086
  35. Cohen NA, Zafer M, Setia N, Anderson MJ, Sakuraba A, Dalal S, Pekow J, Cohen RD, Rubin DT, Micic D. Serum Cytomegalovirus Polymerase Chain Reaction Test Is a Valuable Negative Predictor of Infection in Acute Severe Ulcerative Colitis. Dig Dis Sci. 2022 Jul 04.
    View in: PubMed
    Score: 0.062
  36. Ayoub F, Odenwald M, Micic D, Dalal SR, Pekow J, Cohen RD, Rubin DT, Sakuraba A. Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis. Intest Res. 2022 Apr; 20(2):240-250.
    View in: PubMed
    Score: 0.060
  37. Dwadasi S, Zafer M, Goens D, Paknikar R, Dalal S, Cohen RD, Pekow J, Rubin DT, Sakuraba A, Micic D. Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2021 10 18; 27(10):1620-1625.
    View in: PubMed
    Score: 0.059
  38. Akiyama S, Yamada A, Ollech JE, Komaki Y, Komaki F, Pekow J, Dalal SR, Cohen RD, Rubin DT, Sakuraba A. Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. J Gastroenterol Hepatol. 2021 Oct; 36(10):2785-2793.
    View in: PubMed
    Score: 0.057
  39. Yamada A, Komaki Y, Komaki F, Haider H, Micic D, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Shogan BD, Hurst R, Hyman N, Rubin DT, Sakuraba A. The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. Digestion. 2021; 102(5):767-775.
    View in: PubMed
    Score: 0.056
  40. Patel P, Gao G, Gulotta G, Dalal S, Cohen RD, Sakuraba A, Rubin DT, Pekow J. Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 01 19; 27(2):236-241.
    View in: PubMed
    Score: 0.056
  41. Ollech JE, Avni-Biron I, Glick L, Haider H, Dalal SR, Micic D, Pekow J, Yanai H, Cohen RD, Dotan I, Rubin DT, Sakuraba A. Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clin Gastroenterol Hepatol. 2021 11; 19(11):2444-2446.e2.
    View in: PubMed
    Score: 0.055
  42. Ollech JE, Normatov I, Peleg N, Dalal SR, Pekow J, Micic D, Cohen RD, Rubin DT, Sakuraba A. Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
    View in: PubMed
    Score: 0.054
  43. Wang J, Prenner J, Wang W, Sakuraba A, Hyman N, Dalal S, Hurst R, Cohen RD, Umanskiy K, Shogan BD, Alpert L, Rubin DT, Colwell J, Pekow J. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.053
  44. Ollech JE, Normatov I, Peleg N, Wang J, Patel SA, Rai V, Yi Y, Singer J, Dalal SR, Sakuraba A, Cohen RD, Rubin DT, Pekow J. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2021 01; 19(1):104-110.
    View in: PubMed
    Score: 0.053
  45. Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.050
  46. Ollech JE, Rubin DT, Glick L, Weisshof R, El Jurdi K, Israel A, Krugliak Cleveland N, Hyman N, Sakuraba A, Pekow J, Cohen RD, Dalal SR. Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019 12; 64(12):3596-3601.
    View in: PubMed
    Score: 0.050
  47. Alpert L, Yassan L, Poon R, Kadri S, Niu N, Patil SA, Mujacic I, Montes D, Galbo F, Wurst MN, Zhen CJ, Cohen RD, Rubin DT, Pekow JR, Weber CR, Xiao SY, Hart J, Segal J, Setia N. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
    View in: PubMed
    Score: 0.050
  48. Ollech JE, Aharoni-Golan M, Weisshof R, Normatov I, Sapp AR, Kalakonda A, Israel A, Glick LR, Karrison T, Dalal SR, Sakuraba A, Cohen RD, Rubin DT, Pekow J. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
    View in: PubMed
    Score: 0.049
  49. Anyane-Yeboa A, Yamada A, Haider H, Wang Y, Komaki Y, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A. A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940.
    View in: PubMed
    Score: 0.047
  50. Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
    View in: PubMed
    Score: 0.047
  51. Yamada A, Komaki Y, Patel N, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
    View in: PubMed
    Score: 0.046
  52. Micic D, Gaetano JN, Rubin JN, Cohen RD, Sakuraba A, Rubin DT, Pekow J. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900.
    View in: PubMed
    Score: 0.044
  53. Yamada A, Komaki Y, Patel N, Komaki F, Aelvoet AS, Tran AL, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
    View in: PubMed
    Score: 0.044
  54. Meckel K, Li YC, Lim J, Kocherginsky M, Weber C, Almoghrabi A, Chen X, Kaboff A, Sadiq F, Hanauer SB, Cohen RD, Kwon J, Rubin DT, Hanan I, Sakuraba A, Yen E, Bissonnette M, Pekow J. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20.
    View in: PubMed
    Score: 0.041
  55. Bellaguarda E, Keyashian K, Pekow J, Rubin DT, Cohen RD, Sakuraba A. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1919-25.
    View in: PubMed
    Score: 0.038
  56. Afif W, Leighton JA, Hanauer SB, Loftus EV, Faubion WA, Pardi DS, Tremaine WJ, Kane SV, Bruining DH, Cohen RD, Rubin DT, Hanson KA, Sandborn WJ. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.